Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Terminated Not applicable Interventional

Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction

NCT01326091
View directory record Official record
Conditions
Intervertebral Disk Degeneration
Interventions
Hyperlordotic Positioning
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 23, 2026, 9:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

NCT06679582
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Luveltamab tazevibulin
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
1 Day to 12 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Recruiting Phase 1 Interventional

OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

NCT07655583
View directory record Official record
Conditions
Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
Interventions
Systemic therapy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion

NCT04574388
View directory record Official record
Conditions
Spine Surgery
Interventions
open label placebo
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 23, 2026, 9:58 PM EDT
Completed No phase listed Observational

Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery

NCT04221594
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Invasive Cardiac Catheterization (ICA), Coronary Computed Tomographic Angiogram (CCTA), Dynamic Cardiac Positron Emission Tomography (dPET)
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 9:58 PM EDT
Terminated No phase listed Observational

Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas

NCT00639405
View directory record Official record
Conditions
Parathyroid Neoplasm, Parathyroid Diseases
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 23, 2026, 9:58 PM EDT
Not listed No phase listed Observational

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

NCT04697446
View directory record Official record
Conditions
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Metastatic Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 23, 2026, 9:58 PM EDT
Completed No phase listed Observational

Comprehensive Spinal Alignment Planning Study

NCT02606695
View directory record Official record
Conditions
Spine Surgery
Interventions
NuvaMap O.R., NuvaMap
Device
Lead sponsor
NuVasive
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 23, 2026, 9:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

NCT04060407
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
CD24Fc, Ipilimumab, Nivolumab
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 23, 2026, 9:58 PM EDT
Withdrawn Not applicable Interventional

Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients

NCT01566422
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Vancomycin powder
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 23, 2026, 9:58 PM EDT
Suspended Phase 1Phase 2 Interventional

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

NCT04855253
View directory record Official record
Conditions
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
Interventions
E7777, Fludarabine, Cyclophosphamide, Tisagenlecleucel, Axicabtagene Ciloleucel, Lisocabtagene Maraleucel Intravenous Suspension
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

M7824 in Subjects With HPV Associated Malignancies

NCT03427411
View directory record Official record
Conditions
Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer
Interventions
M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
0 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 9:58 PM EDT
Terminated Phase 2 Interventional Results available

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

NCT01441765
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
CT-011, DC/RCC fusion vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Phase 4 Interventional

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

NCT00337701
View directory record Official record
Conditions
HIV Infections
Interventions
enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 23, 2026, 9:58 PM EDT
Completed No phase listed Observational

Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1

NCT06909292
View directory record Official record
Conditions
Sacroiliac Joint Dysfunction
Interventions
Sacroiliac Joint transfixing and fusion system (Nevro1)
Device
Lead sponsor
Nevro Corp
Industry
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Lodi, California • Southfield, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Phase 1Phase 2 Interventional

A Treatment Study of Mucopolysaccharidosis Type IIIB

NCT02754076
View directory record Official record
Conditions
MPS III B, Mucopolysaccharidosis Type IIIB
Interventions
AX 250
Drug
Lead sponsor
Allievex Corporation
Industry
Eligibility
1 Year to 10 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF

NCT00437190
View directory record Official record
Conditions
Radiculopathy, Myelopathy, Cervical Degenerative Disc Disease
Interventions
ATLANTIS™ Cervical Plate System and allograft, BRYAN Cervical Disc Prosthesis
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
21 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Campbell, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 23, 2026, 9:58 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Elderly Deformity Surgery

NCT02035280
View directory record Official record
Conditions
Adult Spinal Deformity
Interventions
Not listed
Lead sponsor
AO Foundation, AO Spine
Other
Eligibility
60 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
San Francisco, California • Minneapolis, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 23, 2026, 9:58 PM EDT
Not yet recruiting No phase listed Observational

Postsurgical Pain and Opioid Use in Older Adults: Effects of Mild Cognitive Impairment

NCT07885085
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Opioid Use, Cognitive Dysfunction, Postoperative Pain
Interventions
Not listed
Lead sponsor
Miklos Kertai
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Recruiting Phase 2 Interventional

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Interventions
TAS-120
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
La Jolla, California • Tampa, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Not listed Not applicable Interventional

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

NCT04656678
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Device
Lead sponsor
Northwell Health
Other
Eligibility
45 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Results available

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 23, 2026, 9:58 PM EDT